Surgery Partners, Inc. (NASDAQ:SGRY) Shares Sold by Royce & Associates LP

Royce & Associates LP decreased its holdings in Surgery Partners, Inc. (NASDAQ:SGRY) by 95.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,347 shares of the company’s stock after selling 485,914 shares during the quarter. Royce & Associates LP’s holdings in Surgery Partners were worth $515,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SGRY. Natixis Advisors LLC grew its position in Surgery Partners by 3.0% during the 3rd quarter. Natixis Advisors LLC now owns 12,828 shares of the company’s stock worth $414,000 after purchasing an additional 376 shares in the last quarter. KBC Group NV grew its position in Surgery Partners by 31.8% during the 3rd quarter. KBC Group NV now owns 2,385 shares of the company’s stock worth $77,000 after purchasing an additional 576 shares in the last quarter. MeadowBrook Investment Advisors LLC grew its position in Surgery Partners by 16.6% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company’s stock worth $218,000 after purchasing an additional 1,460 shares in the last quarter. Rhumbline Advisers grew its position in Surgery Partners by 1.3% during the 4th quarter. Rhumbline Advisers now owns 121,852 shares of the company’s stock worth $2,580,000 after purchasing an additional 1,588 shares in the last quarter. Finally, Pier Capital LLC grew its position in Surgery Partners by 0.5% during the 3rd quarter. Pier Capital LLC now owns 329,882 shares of the company’s stock worth $10,635,000 after purchasing an additional 1,589 shares in the last quarter.

Wall Street Analyst Weigh In

SGRY has been the topic of several research analyst reports. Bank of America initiated coverage on shares of Surgery Partners in a research report on Monday, December 16th. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research note on Tuesday, December 3rd. Finally, Macquarie decreased their target price on shares of Surgery Partners from $34.00 to $33.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.63.

Insider Activity at Surgery Partners

In related news, CFO David T. Doherty sold 13,641 shares of Surgery Partners stock in a transaction on Friday, February 7th. The shares were sold at an average price of $25.61, for a total value of $349,346.01. Following the transaction, the chief financial officer now owns 108,862 shares in the company, valued at $2,787,955.82. This trade represents a 11.14 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Harrison R. Bane sold 56,315 shares of Surgery Partners stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the transaction, the insider now owns 107,037 shares in the company, valued at $2,744,428.68. This trade represents a 34.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 106,622 shares of company stock valued at $2,717,860. Insiders own 2.30% of the company’s stock.

Surgery Partners Stock Down 0.7 %

SGRY stock opened at $24.21 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. Surgery Partners, Inc. has a 1 year low of $19.50 and a 1 year high of $33.97. The company has a fifty day simple moving average of $23.93 and a 200 day simple moving average of $25.82. The firm has a market cap of $3.09 billion, a PE ratio of -50.44, a PEG ratio of 19.21 and a beta of 2.73.

Surgery Partners (NASDAQ:SGRY) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.01. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $828.09 million. Sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.